Section Editor: Allison Osmond MD FRCPC
June 14, 2026
Pathologists use the term atypical melanocytic proliferation to describe a skin growth composed of melanocytes (the cells that produce pigment) that does not appear completely normal under the microscope. The growth shows some unusual or atypical features, but not all of the features needed to confidently call it benign (noncancerous) or malignant (cancerous). It is best thought of as a description of uncertainty rather than a final diagnosis. This article explains what the term means, what the findings in your pathology report describe, and how those findings guide the next steps in your care.
An atypical melanocytic proliferation is not the same as a diagnosis of cancer. At the same time, it does not completely rule out the possibility that the growth could behave like a melanoma (a type of skin cancer). The term reflects genuine uncertainty about whether the growth is benign or malignant, and pathologists use it when the features under the microscope make a definite diagnosis difficult. It is a way of saying that the growth needs careful evaluation and follow-up to ensure nothing is missed.
On the skin’s surface, an atypical melanocytic proliferation may resemble other nevi (moles) or pigmented spots. Features that may draw attention include:
Because these features can overlap with both harmless and concerning growths, any unusual or changing spot should be examined by a doctor, who may remove a sample for microscopic examination.
The term is applied after a skin growth is biopsied or removed and examined under the microscope by a pathologist. Under the microscope, melanocytes may appear larger, darker, or more irregular than normal; they may grow in an unexpected or uneven pattern; and they may extend into the deeper layers of the skin. Often, the growth shows a mix of features seen in benign moles and melanoma, which makes it impossible to confidently place it in either group.
When the features are borderline, pathologists frequently ask one or more colleagues, often a dermatopathologist (a pathologist who specializes in skin diseases), for a second opinion. The clinical context, such as the location of the growth, the patient’s age and history, and how the spot looked and behaved before removal, also helps guide its classification. Additional tests may be used to help in difficult cases, including immunohistochemistry (special stains such as PRAME and p16) and molecular tests (such as FISH or other genetic tests) that look for changes more often found in melanoma.
Because the diagnosis is uncertain, the care team usually takes a cautious approach to protect the patient and avoid unnecessary procedures. The findings in the report, along with the size and location of the growth and the patient’s history, guide what is considered, which may include:
If a fuller evaluation shows the growth is benign, no further treatment beyond routine skin checks is usually needed. If it is reclassified as melanoma, treatment follows the melanoma pathway. Working closely with your doctor is the best way to decide on the right next steps for your situation.